MA37799A1 - Amélioration de l'excitation sexuelle, du désir sexuel, de l'orgasme et/ou du plaisir à la suite d'une administration de prastérone (dha) intra vaginale chez des femmes ne souffrant pas de dyspareunie ou d'autres symptômes d'atrophie vulvo-vaginale ou indépendamment de ceux-ci - Google Patents
Amélioration de l'excitation sexuelle, du désir sexuel, de l'orgasme et/ou du plaisir à la suite d'une administration de prastérone (dha) intra vaginale chez des femmes ne souffrant pas de dyspareunie ou d'autres symptômes d'atrophie vulvo-vaginale ou indépendamment de ceux-ciInfo
- Publication number
- MA37799A1 MA37799A1 MA37799A MA37799A MA37799A1 MA 37799 A1 MA37799 A1 MA 37799A1 MA 37799 A MA37799 A MA 37799A MA 37799 A MA37799 A MA 37799A MA 37799 A1 MA37799 A1 MA 37799A1
- Authority
- MA
- Morocco
- Prior art keywords
- women
- dhea
- vagina
- symptoms
- atrophy
- Prior art date
Links
- FMGSKLZLMKYGDP-USOAJAOKSA-N dehydroepiandrosterone Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC=C21 FMGSKLZLMKYGDP-USOAJAOKSA-N 0.000 title abstract 2
- 230000001568 sexual effect Effects 0.000 title abstract 2
- 208000024891 symptom Diseases 0.000 title abstract 2
- 210000001215 vagina Anatomy 0.000 title abstract 2
- 206010003694 Atrophy Diseases 0.000 title 1
- 230000037444 atrophy Effects 0.000 title 1
- 208000006262 Psychological Sexual Dysfunctions Diseases 0.000 abstract 2
- 206010003693 Atrophic vulvovaginitis Diseases 0.000 abstract 1
- 230000037007 arousal Effects 0.000 abstract 1
- 239000000470 constituent Substances 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000001771 impaired effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
- A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Reproductive Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Endocrinology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Gynecology & Obstetrics (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Pregnancy & Childbirth (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Steroid Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La présente invention concerne une dha intra vaginale utilisée pour le traitement d'au moins un état choisi dans le groupe constitué par un trouble hypoactif du désir sexuel féminin, un trouble de l'excitation sexuelle féminine, un trouble de l'orgasme féminin et un trouble de stimulation de l'intérêt sexuel féminin chez une femme qui (1) ne souffre pas de symptômes d'atrophie vulvo-vaginale et/ou (2) ne souffre pas de dyspareunie de modérée à aiguë.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261675717P | 2012-07-25 | 2012-07-25 | |
| US13/942,977 US20140045806A1 (en) | 2012-07-25 | 2013-07-16 | Sexual arousal, sexual desire, orgasm and/or pleasure following intravaginal prasterone (dhea) administration in women not suffering or independently from dyspareunia or other symptoms of vulvo-vaginal atrophy |
| PCT/CA2013/000654 WO2014015416A1 (fr) | 2012-07-25 | 2013-07-19 | Amélioration de l'excitation sexuelle, du désir sexuel, de l'orgasme et/ou du plaisir à la suite d'une administration de prastérone (dha) intra vaginale chez des femmes ne souffrant pas de dyspareunie ou d'autres symptômes d'atrophie vulvo-vaginale ou indépendamment de ceux-ci |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA37799A1 true MA37799A1 (fr) | 2016-08-31 |
| MA37799B2 MA37799B2 (fr) | 2021-02-26 |
Family
ID=49996456
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA37799A MA37799B2 (fr) | 2012-07-25 | 2013-07-18 | Amélioration de l'excitation sexuelle, du désir sexuel, de l'orgasme et/ou du plaisir à la suite d'une administration de prastérone (dha) intra vaginale chez des femmes ne souffrant pas de dyspareunie ou d'autres symptômes d'atrophie vulvo-vaginale ou indépendamment de ceux-ci |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US20140045806A1 (fr) |
| EP (1) | EP2877183B1 (fr) |
| JP (3) | JP2015522625A (fr) |
| KR (4) | KR102258122B1 (fr) |
| CN (2) | CN111529536A (fr) |
| AR (1) | AR091907A1 (fr) |
| BR (1) | BR112015001479A2 (fr) |
| CA (2) | CA2972491C (fr) |
| CL (1) | CL2015000169A1 (fr) |
| DK (1) | DK2877183T3 (fr) |
| EA (1) | EA028263B1 (fr) |
| ES (1) | ES2848215T3 (fr) |
| HK (1) | HK1204983A1 (fr) |
| IL (1) | IL236868B (fr) |
| IN (1) | IN2014DN10901A (fr) |
| MA (1) | MA37799B2 (fr) |
| MX (2) | MX375078B (fr) |
| MY (1) | MY183944A (fr) |
| NZ (2) | NZ717808A (fr) |
| PH (1) | PH12014502790A1 (fr) |
| SG (1) | SG11201500228UA (fr) |
| TW (1) | TWI693070B (fr) |
| UA (1) | UA114517C2 (fr) |
| WO (1) | WO2014015416A1 (fr) |
| ZA (1) | ZA201409179B (fr) |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020013304A1 (en) * | 1997-10-28 | 2002-01-31 | Wilson Leland F. | As-needed administration of an androgenic agent to enhance female sexual desire and responsiveness |
| EP1441707A1 (fr) * | 2001-11-09 | 2004-08-04 | Pharmacia AB | Agent anti-muscarinique et agoniste des oestrogenes pour traiter une vessie instable ou hyperactive |
| US20060252734A1 (en) * | 2004-09-08 | 2006-11-09 | Woodward John R | Methods of female sexual enhancement |
| US8835413B2 (en) * | 2004-10-20 | 2014-09-16 | Endorecherche, Inc. | Sex steroid precursors alone or in combination with a selective estrogen receptor modulator and/or with estrogens and/or a type 5 cGMP phosphodiesterase inhibitor for the prevention and treatment of vaginal dryness and sexual dysfunction in postmenopausal women |
| US8268806B2 (en) * | 2007-08-10 | 2012-09-18 | Endorecherche, Inc. | Pharmaceutical compositions |
| US20130231317A1 (en) * | 2011-07-19 | 2013-09-05 | Michael S. Riepl | Dhea bioadhesive controlled release gel |
-
2013
- 2013-07-16 US US13/942,977 patent/US20140045806A1/en not_active Abandoned
- 2013-07-18 MA MA37799A patent/MA37799B2/fr unknown
- 2013-07-19 CA CA2972491A patent/CA2972491C/fr not_active Expired - Fee Related
- 2013-07-19 KR KR1020207001389A patent/KR102258122B1/ko active Active
- 2013-07-19 DK DK13822094.2T patent/DK2877183T3/da active
- 2013-07-19 UA UAA201501578A patent/UA114517C2/uk unknown
- 2013-07-19 MY MYPI2015700175A patent/MY183944A/en unknown
- 2013-07-19 ES ES13822094T patent/ES2848215T3/es active Active
- 2013-07-19 BR BR112015001479A patent/BR112015001479A2/pt not_active IP Right Cessation
- 2013-07-19 SG SG11201500228UA patent/SG11201500228UA/en unknown
- 2013-07-19 KR KR20157002158A patent/KR20150033696A/ko not_active Ceased
- 2013-07-19 CA CA2879648A patent/CA2879648C/fr not_active Expired - Fee Related
- 2013-07-19 CN CN202010122058.9A patent/CN111529536A/zh active Pending
- 2013-07-19 HK HK15105870.7A patent/HK1204983A1/xx unknown
- 2013-07-19 EP EP13822094.2A patent/EP2877183B1/fr active Active
- 2013-07-19 NZ NZ717808A patent/NZ717808A/en not_active IP Right Cessation
- 2013-07-19 EA EA201500165A patent/EA028263B1/ru unknown
- 2013-07-19 JP JP2015523354A patent/JP2015522625A/ja active Pending
- 2013-07-19 KR KR1020177022207A patent/KR20170095399A/ko not_active Ceased
- 2013-07-19 WO PCT/CA2013/000654 patent/WO2014015416A1/fr not_active Ceased
- 2013-07-19 KR KR1020217015590A patent/KR20210062746A/ko not_active Ceased
- 2013-07-19 MX MX2015001064A patent/MX375078B/es active IP Right Grant
- 2013-07-19 CN CN201380037621.0A patent/CN104540511A/zh active Pending
- 2013-07-19 NZ NZ703168A patent/NZ703168A/en not_active IP Right Cessation
- 2013-07-24 TW TW102126477A patent/TWI693070B/zh not_active IP Right Cessation
- 2013-07-25 AR ARP130102659A patent/AR091907A1/es unknown
-
2014
- 2014-12-12 ZA ZA2014/09179A patent/ZA201409179B/en unknown
- 2014-12-15 PH PH12014502790A patent/PH12014502790A1/en unknown
- 2014-12-19 IN IN10901DEN2014 patent/IN2014DN10901A/en unknown
-
2015
- 2015-01-22 IL IL236868A patent/IL236868B/en active IP Right Grant
- 2015-01-23 CL CL2015000169A patent/CL2015000169A1/es unknown
- 2015-01-23 MX MX2020009333A patent/MX2020009333A/es unknown
-
2016
- 2016-12-01 JP JP2016233998A patent/JP6618887B2/ja active Active
-
2019
- 2019-08-16 JP JP2019149357A patent/JP6893960B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201491334A1 (ru) | Композиции и способы для лечения метаболических расстройств | |
| PH12019501339A1 (en) | Amino acid compositions and methods for the treatment of muscle diseases and disorders | |
| EA201270767A1 (ru) | Терапия на основе лигандов хемосенсорных рецепторов | |
| IN2014KN02830A (fr) | ||
| JO3462B1 (ar) | أجسام مضادة بشرية تجاه gfr?3 وطرق لاستخدامها | |
| WO2015085143A3 (fr) | Agents thérapeutiques pour maladies et affections cutanées | |
| EA201690964A1 (ru) | Композиции и способы для уменьшения серьезных неблагоприятных сердечно-сосудистых явлений | |
| MX2015010296A (es) | Tratamiento de formas progresivas de esclerosis multiple con laquinimod. | |
| BR112015010039A2 (pt) | tratamento de câncer com pomalidomida em um individuo com disfunção renal | |
| EA201391440A1 (ru) | Производные пиразолопиримидина | |
| EA201391702A1 (ru) | Интраназальные тестостероновые составы с пониженной дозировкой в виде геля и их применение для лечения аноргазмии или гипоактивного расстройства сексуального желания | |
| BR112015010639A2 (pt) | lactobacillus rhamnosus para redução da acumulação de gordura corporal | |
| MX2016008027A (es) | Uso de laquinimod para retrasar la evolucion de la enfermedad de huntington. | |
| SI2694065T1 (en) | A composition for treating a disorder of hypoactive sexual desire | |
| MA37799A1 (fr) | Amélioration de l'excitation sexuelle, du désir sexuel, de l'orgasme et/ou du plaisir à la suite d'une administration de prastérone (dha) intra vaginale chez des femmes ne souffrant pas de dyspareunie ou d'autres symptômes d'atrophie vulvo-vaginale ou indépendamment de ceux-ci | |
| EA201492238A1 (ru) | Композиция мизопростола | |
| WO2015051234A3 (fr) | Antagonistes de tweak pour traiter la néphropathie lupique et l'atrophie musculaire | |
| EA201590760A1 (ru) | Применение бремеланотида в терапии женской сексуальной дисфункции | |
| TH1501000324A (th) | การปรับปรุงให้ดีขึ้นของความตื่นตัวทางเพศ, ความต้องการทางเพศ, ความเสียวสุดยอดทางเพศ และ/หรือ ความพึงพอใจ หลังการให้พราสเตอโรน (dhea) ในช่องคลอดในผู้หญิงที่ไม่มีหรือเป็นอิสระจากอาการปวดเฉียบขณะ ร่วมเพศหรืออาการอื่นๆ ของโยนีและช่องคลอดฝ่อลีบ | |
| BRPI1104941A8 (pt) | Produto nanotecnológico de uma formulação lipossomal elástica para o tratamento da obesidade, lipoma, lipodistrofia e gorduras subcutâneas | |
| Chernenkov et al. | The experience with the use of synbiotic in patients of a pediatric hospital | |
| IN2014KN01142A (fr) | ||
| UA93416C2 (ru) | Способ оценки симптомов преждевременной эякуляции | |
| HK1227697A1 (en) | Tweak antagonists for treating lupus nephritis and muscle atrophy | |
| MX2016011140A (es) | Composiciones sinergisticas de aminas simpaticomimeticas, 5-hidroxitriptofano y carbidopa para la perdida de peso. |